explore -WSS

explore

author：Wikipedia 2025-09-27 23:52:08 - browse：9

Verve Therapeutics CEO Sekar Kathiresan Verve

SAN FRANCISCO — The promise of genome editing has given rise to potentially curative medicines for rare, life-threatening diseases that generally affect small numbers of patients. But since Verve Therapeutics was founded in 2018, it’s had a wider aperture: using the molecular tools of genome editing to go after the most common cause of death in the world.

The plan, according to Verve CEO Sekar Kathiresan, is to edit out heart attacks for the millions of people at risk for severe cardiovascular disease. It’s a goal that’s more than a little audacious. There’s just one approved genome editing medicine, a treatment for sickle cell disease, and it only passed Food and Drug Administration review last month. Base editing, the CRISPR successor Verve uses to conduct its molecular surgery, is only a few years old.

“When we started, there were so many things that we were kind of going against the grain on,” Kathiresan told STAT at the J.P. Morgan Healthcare Conference in San Francisco this week. “In 2018, it was all about platforms, not about specific diseases and products, or taking this kind of idea for a large indication as opposed to cancer or rare disease. But we’ve always been motivated by a deep conviction in one simple research insight, which is that if your blood cholesterol is really low, lifelong, it is very hard to get a heart attack.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

WSS

Data integrity in scientific journals requires "effort" by publishers, institutions

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Arc Institute generative AI designs new CRISPR systems

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Readout LOUD podcast: A CRISPR milestone, biotech mixology

Morphosys mixed study results for blood cancer drug

hotspot

explore

hotspot

Alkermes shareholders re

Glen Campbell's doctor discusses his public struggle with Alzheimer's

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Morphosys mixed study results for blood cancer drug

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Anxious about a speech? A startup wants you to pop a minty cardiac drug

At least 13 dead in Texas as scorching temps continue

Can we make enough H5N1 bird flu vaccine if there's a pandemic?

The high cost of giving birth even with insurance

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

focus

Cytokinetics CEO stresses company can launch heart drug on its own

Morphosys mixed study results for blood cancer drug

Anthos stroke drug appears safer than common blood thinner

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

It's time to retire 'poor historian' from clinicians' vocabularies

hotspot

explore

knowledge

focus